Article

HTA Quarterly Fall 2024

In this special themed edition, our colleagues at Vintura, a Cencora company, explore the potential of value-based partnerships (VBPs). First outlining the principles, goals, and potential benefits of VBPs, this edition also provides two case studies that demonstrate how successful partnerships work in practice.
VBHC

Embracing value-based partnerships: A path to enhanced healthcare outcomes

Understand when value-based partnerships in healthcare create the most impact for patients, and learn how to forge those alliances.

Heard on the street

“Harmonizing methodological choices between drug developers and assessors presents a promising avenue towards enhancing accuracy and reliability in HTAs.”


Dr. Michael Hennig, Senior Director, Expertise Line Head for HTA Statistics at PharmaLex, a Cencora company, comments on the new EU guidelines on statistical analysis set to impact biopharmaceutical companies starting in January 2025.

Source: Q&A on the latest guidelines for statistical analysis in EU Health Technology Assessment (amerisourcebergen.com)

By the numbers

9% - The price of confidentiality

Under the German Medical Research Act (MFG), which will come into effect on January 1, 2025, pharma companies with R&D departments in Germany will be able to choose between transparent or confidential pricing. Those who choose the confidential option agree to an automatic 9% discount on the agreed-on price of a new patented medicine. The difference between the public price and the agreed-on discounted price under Germany’s AMNOG process will be reimbursed by the company. 

Source: Germany inches closer to confidential pricing for drugs | pharmaphorum

 

Article

Embracing value-based partnerships: A path to enhanced healthcare outcomes

Article

Innovative clinical trial design

We’re here to help

Connect with our team today to learn more about how Cencora is helping to shape the future of healthcare.

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.